A Phase 2 interventional study of Ramucirumab and Placebo in Metastatic Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 34 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-03-08.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B. (Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Drug: Ramucirumab · Drug: S-1 · Drug: Oxaliplatin · Drug: Paclitaxel
(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B. (Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
Drug: Ramucirumab · Drug: Placebo · Drug: S-1 · Drug: Oxaliplatin · Drug: Paclitaxel
Administered IV
Also known as: LY3009806, IMC-1121B, Cyramza
Administered IV
Drug pages: Tegafur · Gimeracil · Oxonic Acid
Administered PO
Administered IV
Administered IV
Progression Free Survival (PFS)
PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 millimeter (mm) or the appearance of ≥1 new lesions was progression. Participants who did not progress, were lost to follow-up were censored at the day of their last adequate tumor assessment.
Time frame: Randomization to Radiographic Documentation of Progression or Death Due to Any Cause (Up to 25 Months)
Progression-free Survival to the Second Disease Progression (PFS 2)
Progression-free survival 2 (PFS2) is defined as the time from the date of randomization to second disease progression (defined as the date of first tumor assessment observing PD defined by RECIST v.1.1, after the start of second-line therapy using the last tumor assessment before starting the second-line therapy (RAM+PTX) as the baseline assessment), or death of any cause, whichever occurs first. If the second-line therapy was not started, the OS will be substituted for PFS2. If a post-discontinuation therapy was started before observing PD after the start of second-line therapy. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. PFS2 will be censored at the date of the last adequate tumor assessment on or before staring the post-discontinuation therapy.
Time frame: Randomization to Second Radiographic Documentation of Progression or Death Due to Any Cause (Up to 31 Months)
Overall Survival (OS)
Overall survival is defined as time from the date of randomization to the date of death from any cause. If the patient was alive at the cut-off for analysis (or lost to follow-up), OS data were censored for analysis on the last date the patient was known to be alive.
Time frame: Randomization to Death Due to Any Cause (Up to 31 Months)
Percentage of Participants With Objective Response Rate (ORR)
The ORR is the number of all participants with Partial Response (PR) or Complete Response (CR) according to RECIST v1.1 from the start of the treatment until disease progression/recurrence. CR is defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 mm. PR is defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm or the appearance of ≥1 new lesions was progression.
Time frame: Randomization to Disease Progression (Up to 25 Months)
Disease Control Rate (DCR)
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm or the appearance of ≥1 new lesions was progression.
Time frame: Randomization to Disease Progression (Up to 25 Months)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A.
Time frame: Cycle 1 Day 1 & 8 Predose, Cycle 2 Day 1 Predose, Cycle 3 Day 1 Predose, Cycle 5 Day 1 Predose, Cycle 9 Day 1 Predose
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B.
Time frame: Cycle 1 Day 1 predose, Cycle 2 Day 1 predose
Number of Participants With Anti-Ramucirumab Antibodies
Participant is considered as treatment emergent anti-drug antibody (TE ADA) positive if the participant has at least one post baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post baseline result of ADA Present with titer \>= 20.
Time frame: Baseline through 25 months
Completers are defined as participants who died or those who were alive and off treatment at study completion.
| Milestone | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Started | 97 | 94 |
| Received any quantity of study drug | 96 | 93 |
| Completed | 77 | 78 |
| Not completed | 20 | 16 |
| Withdrew: Adverse event | 13 | 4 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Physician decision | 4 | 7 |
| Withdrew: Did not receive study drug | 1 | 1 |
| Milestone | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Started | 63 | 66 |
| Completed | 58 | 64 |
| Not completed | 5 | 2 |
| Withdrew: Progressive disease | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Milestone | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Started | 58 | 64 |
| Completed | 54 | 48 |
| Not completed | 4 | 16 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Physician decision | 0 | 9 |
PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 millimeter (mm) or the appearance of ≥1 new lesions was progression. Participants who did not progress, were lost to follow-up were censored at the day of their last adequate tumor assessment.
| Months | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Progression Free Survival (PFS) | 6.34 (5.65 to 6.93) | 6.74 (5.75 to 7.13) |
Progression-free survival 2 (PFS2) is defined as the time from the date of randomization to second disease progression (defined as the date of first tumor assessment observing PD defined by RECIST v.1.1, after the start of second-line therapy using the last tumor assessment before starting the second-line therapy (RAM+PTX) as the baseline assessment), or death of any cause, whichever occurs first. If the second-line therapy was not started, the OS will be substituted for PFS2. If a post-discontinuation therapy was started before observing PD after the start of second-line therapy. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. PFS2 will be censored at the date of the last adequate tumor assessment on or before staring the post-discontinuation therapy.
| Months | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Progression-free Survival to the Second Disease Progression (PFS 2) | 10.94 (9.63 to 12.52) | 11.99 (9.82 to 13.83) |
Overall survival is defined as time from the date of randomization to the date of death from any cause. If the patient was alive at the cut-off for analysis (or lost to follow-up), OS data were censored for analysis on the last date the patient was known to be alive.
| Months | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Overall Survival (OS) | 14.65 (12.39 to 15.67) | 14.26 (13.83 to 17.31) |
The ORR is the number of all participants with Partial Response (PR) or Complete Response (CR) according to RECIST v1.1 from the start of the treatment until disease progression/recurrence. CR is defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 mm. PR is defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm or the appearance of ≥1 new lesions was progression.
| percentage of participants | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Percentage of Participants With Objective Response Rate (ORR) | 58.2 (49.7 to 66.7) | 50.0 (41.3 to 58.7) |
Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm or the appearance of ≥1 new lesions was progression.
| percentage of participants | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Disease Control Rate (DCR) | 90.9 (85.9 to 95.9) | 87 (81.2 to 92.9) |
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A.
| Microgram per milliliter (ug/mL) | Ramucirumab + S-1 + Oxaliplatin - Part A |
|---|---|
| Cycle 1 Day 1 | NA ± NA |
| Cycle 1 Day 8 | 42.6 ± 32 |
| Cycle 2 Day 1 | 41.4 ± 40 |
| Cycle 3 Day 1 | 59.4 ± 51 |
| Cycle 5 Day 1 | 83.6 ± 37 |
| Cycle 9 Day 1 | 94.6 ± 38 |
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B.
| Microgram per milliliter (ug/mL) | Ramucirumab + S-1 + Oxaliplatin Part B | Placebo + S-1 + Oxaliplatin - Part B |
|---|---|---|
| Cycle 1 Day 1 | 52.0 ± 65 | NA ± NA |
| Cycle 2 Day 1 | 58.1 ± 40 | 41.0 ± 45 |
Participant is considered as treatment emergent anti-drug antibody (TE ADA) positive if the participant has at least one post baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post baseline result of ADA Present with titer \>= 20.
| Participants | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin |
|---|---|---|
| Number of Participants With Anti-Ramucirumab Antibodies | 1 | 3 |
Collected over Up to 31 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ramucirumab + S-1 + Oxaliplatin - Part A | 2/96 (2.1%) | 29/96 (30.2%) | 95/96 (99%) |
| Placebo + S-1 + Oxaliplatin - Part A | 1/93 (1.1%) | 24/93 (25.8%) | 93/93 (100%) |
| Ramucirumab + S-1 + Oxaliplatin Part B | 1/58 (1.7%) | 16/58 (27.6%) | 58/58 (100%) |
| Placebo + S-1 + Oxaliplatin - Part B | 0/64 (0%) | 14/64 (21.9%) | 64/64 (100%) |
| Event | Ramucirumab + S-1 + Oxaliplatin - Part A | Placebo + S-1 + Oxaliplatin - Part A | Ramucirumab + S-1 + Oxaliplatin Part B | Placebo + S-1 + Oxaliplatin - Part B |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/96 | 0/93 | 3/58 | 4/64 |
| Gastric perforationGastrointestinal disorders | 1/96 | 1/93 | 3/58 | 0/64 |
| PyelonephritisInfections and infestations | 0/96 | 0/93 | 2/58 | 0/64 |
| Abdominal painGastrointestinal disorders | 1/96 | 3/93 | 1/58 | 0/64 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 3/96 | 0/93 | 0/58 | 1/64 |
| VomitingGastrointestinal disorders | 3/96 | 2/93 | 0/58 | 1/64 |
| AnaemiaBlood and lymphatic system disorders | 0/96 | 2/93 | 0/58 | 0/64 |
| EnterocolitisGastrointestinal disorders | 0/96 | 2/93 | 0/58 | 0/64 |
| Gastric stenosisGastrointestinal disorders | 0/96 | 2/93 | 0/58 | 0/64 |
| DiarrhoeaGastrointestinal disorders | 2/96 | 0/93 | 0/58 | 0/64 |
| Event | Ramucirumab + S-1 + Oxaliplatin - Part A | Placebo + S-1 + Oxaliplatin - Part A | Ramucirumab + S-1 + Oxaliplatin Part B | Placebo + S-1 + Oxaliplatin - Part B |
|---|---|---|---|---|
| Peripheral sensory neuropathyNervous system disorders | 56/96 | 70/93 | 8/58 | 14/64 |
| Decreased appetiteMetabolism and nutrition disorders | 53/96 | 57/93 | 9/58 | 12/64 |
| Neutrophil count decreasedInvestigations | 48/96 | 32/93 | 33/58 | 36/64 |
| NauseaGastrointestinal disorders | 54/96 | 37/93 | 5/58 | 4/64 |
| DiarrhoeaGastrointestinal disorders | 49/96 | 28/93 | 10/58 | 8/64 |
| AlopeciaSkin and subcutaneous tissue disorders | 10/96 | 2/93 | 26/58 | 30/64 |
| White blood cell count decreasedInvestigations | 24/96 | 18/93 | 19/58 | 24/64 |
| ConstipationGastrointestinal disorders | 33/96 | 30/93 | 3/58 | 6/64 |
| Platelet count decreasedInvestigations | 33/96 | 28/93 | 4/58 | 4/64 |
| VomitingGastrointestinal disorders | 28/96 | 21/93 | 5/58 | 7/64 |
All randomized participants who received any quantity of study drug.
| Age, Continuous(Years) | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin | Total |
|---|---|---|---|
| Mean | 59.2 ± 12.35 | 61.3 ± 11.53 | 60.2 ± 11.97 |
| Sex: Female, Male(Participants) | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin | Total |
|---|---|---|---|
| Female | 39 | 29 | 68 |
| Male | 57 | 64 | 121 |
| Ethnicity (NIH/OMB)(Participants) | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 96 | 93 | 189 |
| Race (NIH/OMB)(Participants) | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 96 | 93 | 189 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Ramucirumab + S-1 + Oxaliplatin | Placebo + S-1 + Oxaliplatin | Total |
|---|---|---|---|
| South Korea | 20 | 20 | 40 |
| Japan | 65 | 64 | 129 |
| Taiwan | 11 | 9 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2015 to primary completion in Oct 2017, 24 months.
Results were first posted in Feb 2019, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Oxaliplatin · Paclitaxel